泰格医药
(300347)
| 流通市值：305.14亿 | | | 总市值：462.92亿 |
| 流通股本：5.70亿 | | | 总股本：8.65亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,603,120,162.78 | 5,067,615,359.89 | 3,358,244,223.39 | 1,660,204,321.44 |
| 营业收入 | 6,603,120,162.78 | 5,067,615,359.89 | 3,358,244,223.39 | 1,660,204,321.44 |
| 二、营业总成本 | 5,610,048,004.89 | 4,026,550,519.06 | 2,626,269,846.32 | 1,305,287,804.37 |
| 营业成本 | 4,361,106,945.65 | 3,097,333,423.23 | 2,025,196,633.7 | 1,032,080,670.15 |
| 税金及附加 | 28,038,219.79 | 22,385,614.14 | 14,493,882.32 | 7,700,539 |
| 销售费用 | 207,607,782.45 | 144,935,323.39 | 101,377,890.5 | 46,452,309.63 |
| 管理费用 | 736,842,477.93 | 558,426,318.44 | 376,615,946.18 | 177,068,490.82 |
| 研发费用 | 238,385,545.75 | 172,098,760.28 | 124,694,222.85 | 63,906,152.52 |
| 财务费用 | 38,067,033.32 | 31,371,079.58 | -16,108,729.23 | -21,920,357.75 |
| 其中:利息费用 | 141,235,382.04 | - | 67,432,236.02 | - |
| 其中:利息收入 | 90,219,275.91 | - | 71,381,356.68 | - |
| 加:公允价值变动收益 | -501,688,166.32 | -34,411,947.15 | -98,403,141.06 | 12,753,272.78 |
| 加:投资收益 | 166,642,230.65 | 109,158,171.38 | 70,743,456.58 | -3,591,151.18 |
| 资产处置收益 | 3,563,278.83 | 2,674,931.25 | 1,489,722.71 | 1,152,370.67 |
| 资产减值损失(新) | 1,254,555.47 | -10,657,299.51 | -8,424,529.23 | -7,752,329.78 |
| 信用减值损失(新) | -35,275,311.28 | -44,439,217.18 | -27,659,162.33 | -10,652,196.93 |
| 其他收益 | 36,850,266.27 | 21,606,421.27 | 17,348,696.48 | 15,369,745.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 664,419,011.51 | 1,084,995,900.89 | 687,069,420.22 | 362,196,228.41 |
| 加:营业外收入 | 5,090,122.07 | 5,337,204.28 | 4,950,417.77 | 301,243.15 |
| 减:营业外支出 | 5,047,625.28 | 3,268,133.42 | 1,926,665.02 | 133,267.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 664,461,508.3 | 1,087,064,971.75 | 690,093,172.97 | 362,364,203.95 |
| 减:所得税费用 | 216,630,221.33 | 183,929,494.79 | 132,514,479.05 | 49,793,830.56 |
| 六、净利润 | 447,831,286.97 | 903,135,476.96 | 557,578,693.92 | 312,570,373.39 |
| 持续经营净利润 | 447,831,286.97 | 903,135,476.96 | 557,578,693.92 | 312,570,373.39 |
| 归属于母公司股东的净利润 | 405,143,491.82 | 813,428,915.46 | 492,848,850.97 | 235,072,002.7 |
| 少数股东损益 | 42,687,795.15 | 89,706,561.5 | 64,729,842.95 | 77,498,370.69 |
| (一)基本每股收益 | 0.47 | 0.94 | 0.57 | 0.27 |
| (二)稀释每股收益 | 0.47 | 0.94 | 0.57 | 0.27 |
| 八、其他综合收益 | -30,367,462.62 | -50,709,884.36 | -30,370,935.25 | -22,239,213.91 |
| 归属于母公司股东的其他综合收益 | -4,438,571.01 | -26,157,226.69 | -12,320,083.43 | -7,569,853.71 |
| 九、综合收益总额 | 417,463,824.35 | 852,425,592.6 | 527,207,758.67 | 290,331,159.48 |
| 归属于母公司股东的综合收益总额 | 400,704,920.81 | 787,271,688.77 | 480,528,767.54 | 227,502,148.99 |
| 归属于少数股东的综合收益总额 | 16,758,903.54 | 65,153,903.83 | 46,678,991.13 | 62,829,010.49 |
| 公告日期 | 2025-03-28 | 2024-10-30 | 2024-08-29 | 2024-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |